Suppr超能文献

婴儿期的抑酸治疗与12月龄时的贫血风险

Acid-suppressive therapy among infants and risk of anemia at 12 months of age.

作者信息

Abu-Sulb Ahmad, Al-Najjar Rawan, Maghnam Rama, Ashhab Ashraf

机构信息

Division of Pediatrics, Legacy Community Health, Houston, TX, USA.

Division of Neonatology, Baylor College of Medicine, Houston, TX, USA.

出版信息

SAGE Open Med. 2022 Sep 8;10:20503121221123117. doi: 10.1177/20503121221123117. eCollection 2022.

Abstract

OBJECTIVES

Numerous studies have shown that links exist between exposure to acid suppression among adults and nutritional deficiencies, especially vitamin B12 and iron. While the use of acid suppression among children and infants is common, nutritional deficiency remains a concern but does not have numerous studies to support it. We conducted a cohort study to examine this concern; the hypothesis we proposed is that acid-suppressive therapy (AST) during infancy is linked to anemia in the first year of life.

METHODS

This retrospective cohort study included infants born between 2017 and 2018 who visited Legacy Community Health. The inclusion criteria were exposure to acid suppression for a minimum of 1 month and a hemoglobin reading at 12-15 months. Infants who had hemoglobinopathies, failure to thrive, or malabsorption syndromes were excluded. Mean hemoglobin was calculated, and student's -test was applied to find statistical differences between the two groups. Change in weight before and after treatment was recorded. Occurrence of respiratory and gastroenterological adverse events was recorded in the exposed group.

RESULTS

Overall, 135 exposed infants were identified 135 controls were selected. The majority of the sample included Hispanic girls. Ranitidine was the most commonly prescribed medicine. The duration of treatment was 3 months. Weight improved significantly at termination of the treatment. There was no significant difference between the hemoglobin level of cases and controls, and both were not considered anemic.

CONCLUSION

AST was not linked to anemia, despite the slightly lower hemoglobin in some cases. There were few weaknesses in our study; therefore, further studies can examine this link by focusing further on medication type and close follow-up. We found that although proton pump inhibitors are considered the first line of treatment, histamine-2 receptor antagonists were more frequently prescribed. Strategies to familiarize general pediatricians with the NSAPGHAN guidelines might be needed.

摘要

目的

众多研究表明,成人使用抑酸药物与营养缺乏之间存在关联,尤其是维生素B12和铁缺乏。虽然儿童和婴儿使用抑酸药物的情况很常见,但营养缺乏仍是一个问题,不过缺乏大量研究来支持这一观点。我们进行了一项队列研究来探讨这一问题;我们提出的假设是,婴儿期的抑酸治疗(AST)与出生后第一年的贫血有关。

方法

这项回顾性队列研究纳入了2017年至2018年在遗产社区健康中心就诊的婴儿。纳入标准为接受至少1个月的抑酸治疗,且在12至15个月时进行血红蛋白检测。患有血红蛋白病、发育不良或吸收不良综合征的婴儿被排除。计算平均血红蛋白水平,并应用学生t检验来发现两组之间的统计学差异。记录治疗前后的体重变化。记录暴露组中呼吸和胃肠不良事件的发生情况。

结果

总体而言,共确定了135名暴露婴儿,并选择了135名对照。样本中的大多数是西班牙裔女孩。雷尼替丁是最常用的药物。治疗持续时间为3个月。治疗结束时体重显著改善。病例组和对照组的血红蛋白水平无显著差异,且两者均未被视为贫血。

结论

尽管在某些情况下血红蛋白略低,但AST与贫血无关。我们的研究存在一些不足之处;因此,进一步的研究可以通过更关注药物类型和密切随访来研究这种关联。我们发现,虽然质子泵抑制剂被认为是一线治疗药物,但组胺-2受体拮抗剂的处方更为频繁。可能需要采取策略让普通儿科医生熟悉NSAPGHAN指南。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验